There are 2789 resources available
475P - A phase Ib study of NUC-3373, a targeted inhibitor of thymidylate synthase, in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302)
Presenter: Jordan Berlin
Session: ePoster Display
536P - Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
Presenter: Theodore W. Laetsch
Session: ePoster Display
537P - Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine care
Presenter: Stefanie Krens
Session: ePoster Display
539P - Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
Presenter: Jianming Xu
Session: ePoster Display
540P - Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4
Presenter: David Hong
Session: ePoster Display
476P - Open-label phase I/II study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)
Presenter: Talia Shentzer Kutiel
Session: ePoster Display
477P - Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Heinz Josef Lenz
Session: ePoster Display
478P - TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
Presenter: Cristina Santos
Session: ePoster Display
591P - A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Rahul Aggarwal
Session: ePoster Display